Predictive Non Currrent Assets Other from 2010 to 2024
| POAI Stock | USD 0.81 0.03 3.85% |
Non Currrent Assets Other | First Reported 2010-09-30 | Previous Quarter 121.1 K | Current Value 102.5 K | Quarterly Volatility 9.1 M |
Check Predictive Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Predictive Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 954.9 K, Interest Expense of 12.9 M or Selling General Administrative of 7.1 M, as well as many indicators such as Price To Sales Ratio of 7.05, Dividend Yield of 0.0 or PTB Ratio of 1.52. Predictive financial statements analysis is a perfect complement when working with Predictive Oncology Valuation or Volatility modules.
Predictive | Non Currrent Assets Other |
Latest Predictive Oncology's Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Predictive Oncology over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Predictive Oncology's Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Predictive Oncology's overall financial position and show how it may be relating to other accounts over time.
| Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
| Timeline |
Predictive Non Currrent Assets Other Regression Statistics
| Arithmetic Mean | (1,227,751) | |
| Geometric Mean | 269,566 | |
| Coefficient Of Variation | (459.54) | |
| Mean Deviation | 2,713,266 | |
| Median | 130,301 | |
| Standard Deviation | 5,642,001 | |
| Sample Variance | 31.8T | |
| Range | 22.7M | |
| R-Value | (0.11) | |
| Mean Square Error | 33.9T | |
| R-Squared | 0.01 | |
| Significance | 0.70 | |
| Slope | (137,107) | |
| Total Sum of Squares | 445.7T |
Predictive Non Currrent Assets Other History
About Predictive Oncology Financial Statements
Investors use fundamental indicators, such as Predictive Oncology's Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Predictive Oncology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Non Currrent Assets Other | 124.1 K | 130.3 K |
Currently Active Assets on Macroaxis
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:Check out the analysis of Predictive Oncology Correlation against competitors. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.416 | Quarterly Revenue Growth (0.43) | Return On Assets (0.56) | Return On Equity (1.49) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.